Trial reportBMC pediatrics2026
GERD management in neonatal ICU infants: study protocol for a randomized controlled trial comparing maturation, added rice starch formula and proton pump inhibitors.
Trial report in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06114836 (Pathophysiological Evidence Driven Management of GERD in Neonatal ICU Infants), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pathophysiological Evidence Driven Management of GERD in Neonatal ICU Infants: Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe prevalence of gastroesophageal reflux disease (GERD) diagnosis among infants in the neonatal intensive care unit (NICU) is high and varies across USA NICUs. GERD diagnosis is challenging as symptoms can be physiological and association is difficult to determine without objective testing methods. Precision diagnostics using 24-hour pH-impedance (pH-Imp) studies with symptom correlation to reflux events have been developed and validated for this population. Current empiric-based, non-standardized GERD management practices are highly variable and are widely untested for safety and efficacy in high-risk NICU infants. The rationale for this randomized controlled trial (RCT) is to compare the efficacy and safety of three widely used interventions for infants that meet the criteria for acid-mediated GERD, objectively diagnosed by 24-hour pH-Imp.
methodsThis is a prospective, single-center RCT aiming to enroll convalescing NICU infants between 35- and 47-weeks postmenstrual age with objectively diagnosed GERD using a unique parallel 3-arm design comparing the short-term effects of three common management strategies: natural maturation vs. proton pump inhibitors (PPI) vs. added rice starch (AR) formula. Using established 24-hour pH-Imp inclusion criteria, subjects will be randomized to one of the three arms for a 4-week treatment course allocated 1:1:1, stratified by acid reflux index (ARI) (3-7% and > 7%) and feeding method at inception (full oral versus any tube feeds). Primary outcome measures include maintenance or improvement in oral feeding and symptom improvement measured at 4 weeks or discharge whichever is sooner. A second pH-Imp study will be done on treatment to examine treatment efficacy on GERD metrics. The primary clinical endpoints are oral feeding improvement and absence of troublesome symptoms. The mechanistic hypotheses that pH-Imp mechanisms are distinct between assigned therapies, and between clinical success and failure will also be tested. DISCUSSION: The goal of this study is to refine novel diagnostic pH-Imp criteria for infant GERD diagnosis and compare the efficacy of the three unproven therapies, examine pathophysiological mechanisms for clinical outcomes, define duration of therapy, and assess consequences of interventions.
trial registrationClinicalTrials.gov. Brief Title: GERD Infant Feeding Therapeutics Trial (GIFT Trial). NCT Number: NCT06114836. Unique Protocol ID: STUDY00003300.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.